Randall Kaja

Corporate Officer/Principal en International AIDS Vaccine Initiative, Inc. .

Health Technology

Perfil

Randall Kaja is currently a Partner at the International AIDS Vaccine Initiative, Inc. Prior to this, he worked at Pfizer Inc. from 1996 to 2011, where he held the position of Head-Clinical Operations in 2011.

Cargos activos de Randall Kaja

Empresas	Cargo	Inicio
International AIDS Vaccine Initiative, Inc. International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.	Corporate Officer/Principal	31/05/2011

Todos los cargos activos de Randall Kaja

Antiguos cargos conocidos de Randall Kaja.

Empresas	Cargo	Fin
PFIZER, INC.	Director Técnico/Científico/I+D	01/01/2011

Ver el detalle de la experiencia de Randall Kaja.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Randall Kaja.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
PFIZER, INC.	Health Technology

Empresas privadas	1
International AIDS Vaccine Initiative, Inc. International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.	Health Technology